P&F Products & Features GmbH Strengthens Portfolio with AVVie Acquisition

P&F Products & Features GmbH Strengthens Its Portfolio with AVVie Acquisition

In a significant move to expand its offerings in structural heart technologies, P&F Products & Features GmbH (P&F) has announced the acquisition of AVVie GmbH. This acquisition is expected to bolster P&F's capabilities in providing cutting-edge medical solutions aimed at treating mitral valve diseases, particularly through AVVie's innovative product, the AngelValve™ Augmentation System.

Founded by renowned cardiac surgeon Professor Werner Mohl, AVVie has pioneered remarkable advancements in heart intervention techniques. The AngelValve™ system stands out as a novel transcatheter solution that targets a major health concern: mitral regurgitation, a condition affecting over 13 million individuals across Europe and the United States each year. Mitral regurgitation occurs when blood leaks back into the heart's left atrium, compromising the body's overall health and functionality, but only about 5% of patients with moderate to severe conditions currently receive adequate treatment.

With this acquisition, P&F is aligning itself closer to its mission of addressing the significant treatment gap faced by those suffering from mitral valve issues. By merging AVVie's research and development infrastructure with P&F’s robust experience in product development, manufacturing, and commercial distribution, the companies believe they can significantly accelerate innovation and reduce the time from concept to clinical application.

_P&F’s CEO, Dr. Katharina Kiss, remarked:_ “The acquisition reflects our enduring commitment to advancing groundbreaking therapies for structural heart conditions. Combining AVVie’s engineering brilliance with P&F's strength in navigating clinical trials and regulatory landscapes positions us ideally to push the AngelValve™ platform forward, delivering meaningful advancements for physicians and patients on a global scale. This is an essential step towards becoming a leader in structural heart therapies.”

Dr. Siegfried Einhellig, P&F’s COO and President, echoed her sentiments, stating: “Integrating our talents allows us to transform AVVie’s innovations into proven therapies that can enhance patient care.”

Commitment to Innovation

The acquisition is not merely a financial transaction; it represents a strategic initiative to enhance patient outcomes and overall healthcare quality. P&F’s extensive experience in the cardiovascular realm, spanning over 25 years, encompasses innovation that has reached approximately 70 countries worldwide. The company boasts production facilities across Europe, Asia, and Brazil, enabling a broad scope of impact.

The ramifications of the AngelValve™ addition could be profound. By improving the accessibility of treatment options for patients with limited alternatives, P&F can influence the quality of life for many individuals grappling with this debilitating condition.

Currently, the specific financial terms of the transaction remain undisclosed, but the underlying importance of merging expertise in engineering and clinical application cannot be overstated. As the field of heart interventions evolves, P&F and AVVie’s unified strengths aim to spearhead developments that fundamentally change treatment paradigms for patients with mitral valve disease.

In summary, P&F continues to showcase its ambition to lead in the realm of structural heart therapies through strategic acquisitions that prioritize innovation and patient-centric solutions. With AVVie’s AngelValve™ system added to its portfolio, P&F is set to make a significant impact on the treatment of mitral regurgitation, forging a path towards enhanced medical interventions that can save and improve lives.

To learn more about P&F Products & Features GmbH and their innovative solutions, visit productsandfeatures.com.